1. Home
  2. Advocacy
  3. Latest News and Practice Data
  4. How will FDA’s LDT Rule Impact Your Laboratory and Patients? Share Your Story!

Do you anticipate the Food and Drug Administration’s (FDA) laboratory-developed test final rule creating unnecessary burdens for pathologists or negatively impacting patients’ lives, innovation, or the economy in your community?

Your story could be used to help legislators understand how the oversight of tests should be based on protecting patients and providing access to safe diagnostic tests with a framework that is the least burdensome for pathologists.

Click here, fill out the form, and tell us more.

Most Recent Content

  1. Immunohistochemical Surrogates of Molecular Genetic Alterations in Soft Tissue Tumors
  2. June 24, 2025
  3. CAP talks with CMS about burdens in Medicare
  4. HHS, CMS, and insurers agree on prior authorization changes
  5. Physicians urge reinstatement of vaccine panel
  6. View All